A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy
An Open-label, Multi-center, Phase 2 Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection (PLM60) in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Terminated
The sponsor has adjusted its R\&D strategy.
Other terminated trials from CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Contrast-induced Acute Kidney Injury · Phase PHASE2 · Jan 2024
- Peripheral T Cell Lymphoma · Phase PHASE1 · Nov 2023
- Platinum-resistant Ovarian Cancer · Phase PHASE1 · May 2023
- Unresectable or Metastatic Bone and Soft Tissue Sarcoma · Phase PHASE1 · Feb 2023
- Breast Cancer · Phase PHASE2 · Jan 2023
More terminations from CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A PHASE2 clinical study on Small Cell Lung Cancer, this trial is terminated or withdrawn. The trial is conducted by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. and has accumulated 7 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
-
May 2022 — Apr 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — May 2022 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .